Company intelligence / Profile preview

NimBio

Ownership: Private
Employees: ~4
Development stage: Commercial

Overview

NimBio has successfully completed a clinical proof-of-concept study for its non-invasive flare detection technology. Ongoing clinical validation studies are being conducted at three medical centers. The company presented results at ECCO2024 and DDW2024 conferences. Early data suggest the technology can detect IBD flares before they occur, potentially reducing hospitalizations by up to 50%.

Therapeutic areas: Gastroenterology
Modalities: DeviceDigital health platformAI-powered monitoring system
Industry: Physiological Monitoring

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on NimBio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NimBio.

Explore the full profile